U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Description
Sources: Marieb E (2014). Anatomy & physiology. Glenview, IL: Pearson Education, Inc. ISBN 978-0-321-86158-0.
Curator's Comment: description was created based on several sources, including https://www.medicines.org.uk/emc/medicine/26512 https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204485Orig1s000lbl.pdf

Argipressin is a neurohypophysial hormone from the vasopressin hormone family. Its two primary functions are to retain water in the body and to constrict blood vessels. The antidiuretic action of Argipressin is ascribed to increase in reabsorption of water by the renal tubules. Argipressin can cause contraction of smooth muscle of the gastrointestinal tract, gall bladder, urinary bladder and all parts of the vascular bed, especially the capillaries, small arterioles and venules with less effect on the smooth musculature of the large veins. Agripressin for injections is used for use in diabetes insipidus, when this is not of nephrogenic origin and control of bleeding from oesophageal varices. In addition, argipressin is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.

CNS Activity

Curator's Comment: As a neurotransmitter and/or neuromodulator VP can modulate CNS autonomic systems controlling heart rate, arterial blood pressure, respiration rate, and sleep patterns, however, physiological significance is not understood. VP may also have an effect on certain learned behaviors, in the development of some complex social problems, and in the pathogenesis of complex psychiatric diseases such as depression.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P37288
Gene ID: 552.0
Gene Symbol: AVPR1A
Target Organism: Homo sapiens (Human)
0.24 nM [EC50]
Target ID: P47901
Gene ID: 553.0
Gene Symbol: AVPR1B
Target Organism: Homo sapiens (Human)
0.05 nM [EC50]
Target ID: P30518
Gene ID: 554.0
Gene Symbol: AVPR2
Target Organism: Homo sapiens (Human)
4.3 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Argipressin 20 IU/ml Solution for Injection

Approved Use

For use in diabetes insipidus, when this is not of nephrogenic origin and control of bleeding from oesophageal varices.
Primary
Argipressin 20 IU/ml Solution for Injection

Approved Use

For use in diabetes insipidus, when this is not of nephrogenic origin and control of bleeding from oesophageal varices.
Primary
VASOSTRICT

Approved Use

To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.

Launch Date

2014
Palliative
PITRESSIN

Approved Use

Vasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus
Diagnostic
PITRESSIN

Approved Use

Vasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus.
PubMed

PubMed

TitleDatePubMed
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.
1995 May 15
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
1998 Dec
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
1999 Oct
Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
2000 Apr
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
2000 Oct
Patents

Patents

Sample Use Guides

For treatment of diabetes insipidus: A dose of 0.25ml to 1ml (5 to 20 units) by subcutaneous or intramuscular injection every four hours. For the initial control of variceal bleeding Argipressin should be given intravenously. Argipressin, 20 units diluted in 100ml dextrose 5% w/v may be infused over a 15 minute period.
Route of Administration: Other
Agonist activity of compound at the human vasopressin V1aR was determined in a reporter gene assays (RGA) in HEK293 cells by transiently cotransfecting recombinant vasopressin V1aR expression vectors and the reporter plasmid containing a luciferase gene under the control of NFAT response elements (NFAT-luciferase). Argipressin activates V1aR with EC50 of 0.24 nM.
Substance Class Protein
Created
by admin
on Mon Mar 31 18:20:20 GMT 2025
Edited
by admin
on Mon Mar 31 18:20:20 GMT 2025
Protein Sub Type
Sequence Type COMPLETE
Record UNII
Y4907O6MFD
Record Status FAILED
Record Version
  • Download
Name Type Language
Vasopressin
USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
Argipressin
INN  
Preferred Name English
VASOPRESSIN, 8-ARGININE
Common Name English
VASOPRESSIN [USP MONOGRAPH]
Common Name English
ARGIPRESSIN [MART.]
Common Name English
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (1-6 disulfide)
Systematic Name English
VASOPRESSIN [VANDF]
Common Name English
ARGININE VASOPRESSIN
MI  
Common Name English
VASOPRESSIN [USP-RS]
Common Name English
VASOPRESSIN [ORANGE BOOK]
Common Name English
ARGININE VASOPRESSIN [MI]
Common Name English
argipressin [INN]
Common Name English
Vasopressin [WHO-DD]
Common Name English
VASOSTRICT
Brand Name English
CYS-TYR-PHE-GLN-ASN-CYS-PRO-ARG-GLY-NH2 (1-6 DISULPHIDE)
Common Name English
VASOPRESSIN, 8-L-ARGININE-
Common Name English
Argipressin [WHO-DD]
Common Name English
HBN-1 COMPONENT VASOPRESSIN
Common Name English
8-L-ARGININEVASOPRESSIN
Common Name English
Classification Tree Code System Code
LOINC 26928-2
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
LOINC 3126-0
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
WHO-ATC H01BA01
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
LOINC 14949-2
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
WHO-ATC H01BA06
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
NCI_THESAURUS C80212
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
WHO-VATC QH01BA06
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
LOINC 13903-0
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C926
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
FDA UNII
Y4907O6MFD
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
MERCK INDEX
m11399
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY Merck Index
CHEBI
9937
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
PUBCHEM
644077
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
EPA CompTox
DTXSID0048349
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
LACTMED
Vasopressin
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
ChEMBL
CHEMBL2108986
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
CHEBI
9937
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
ECHA (EC/EINECS)
204-035-4
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
IUPHAR
2168
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
DAILYMED
Y4907O6MFD
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
EVMPD
SUB05082MIG
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
CHEBI
34543
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
CAS
113-79-1
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
RXCUI
1098
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
ALTERNATIVE RxNorm
ChEMBL
CHEMBL373742
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
INN
1482
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
CHEBI
34543
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
RS_ITEM_NUM
1711100
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
RXCUI
11149
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
DRUG BANK
DBSALT002464
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
DRUG BANK
DB00067
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
EVMPD
SUB20776
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
DRUG CENTRAL
2810
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
MESH
D001127
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
EVMPD
SUB05561MIG
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
SMS_ID
100000086520
Created by admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
PRIMARY
From To
1_1 1_6
Related Record Type Details
TARGET -> AGONIST
BINDING
IC50
TARGET -> AGONIST
Ki
TARGET -> AGONIST
Ki
LABELED -> NON-LABELED
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
Ki
Related Record Type Details
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO_ACID_SUBSTITUTION [1_9] C-TERMINUS GLYCINE Amount: GLYCINAMIDE 4JDT453NWO
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL